Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 28, 2013		Dec. 29, 2012		Dec. 31, 2011
Cash flows from operating activities:
Net income	$ 108,967		$ 130,770		$ 169,418
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	98,787		85,371		78,909
Deferred income taxes	24,593		10,338		24,702
Loss/(gain) on sale of assets	(1,245)		1,099		622
Gain on insurance proceeds from insurance settlement	(1,981)		(4,272)		0
Increase/(decrease) in long-term pension liability	(9,010)		2,790		(895)
Stock-based compensation expense	9,433		8,904		3,932
Write-off deferred loan costs	0		725		4,920
Deferred loan cost amortization	3,451		3,042		3,324
Equity in net (income)/loss of unconsolidated subsidiary	(7,660)		2,662		1,572
Unrealized gain on foreign currency hedge	(27,516)		0		0
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable	4,424		(2,324)		(10,086)
Escrow receivable	0		0		16,267
Income taxes refundable	(15,316)		17,845		(15,568)
Inventories and prepaid expenses	2,059		(15,168)		(5,760)
Accounts payable and accrued expenses	8,521		3,923		(29,083)
Other	13,214		3,832		(1,410)
Net cash provided by operating activities	210,721		249,537		240,864
Cash flows from investing activities:
Capital expenditures	(118,307)	[1]	(115,413)	[1]	(60,153)	[1]
Acquisitions, net of cash acquired	(734,075)		(3,000)		(1,754)
Investment in unconsolidated subsidiary	(44,959)		(43,424)		(23,305)
Gross proceeds from sale of property, plant and equipment and other assets	2,358		3,870		1,529
Proceeds from Insurance Settlement	1,981		4,272		0
Payments related to routes and other intangibles	(2,423)		(137)		0
Net cash used by investing activities	(895,425)		(153,832)		(83,683)
Cash flows from financing activities:
Proceeds from long-term debt	344,704		0		0
Payments on long-term debt	(580)		(30,032)		(270,009)
Borrowings from revolving credit facility	293,235		0		131,000
Payments on revolving credit facility	(5,000)		0		(291,000)
Deferred loan costs	(13,320)		0		(399)
Issuance of common stock	840,558		72		293,117
Minimum withholding taxes paid on stock awards	(3,289)		(4,084)		(1,281)
Excess tax benefits from stock-based compensation	1,138		2,652		1,125
Net cash provided/(used) in financing activities	1,457,446		(31,392)		(137,447)
Effect of Exchange Rate on Cash and Cash Equivalents	(5,134)		0		0
Net increase/(decrease) in cash and cash equivalents	767,608		64,313		19,734
Cash and cash equivalents at beginning of year	103,249		38,936		19,202
Cash and cash equivalents at end of year	870,857		103,249		38,936
Supplemental disclosure of cash flow information:
Accrued capital expenditures	1,163		0		0
Cash paid during the period for:
Interest, net of capitalized interest	21,554		20,181		28,690
Income taxes, net of refunds	31,405		43,491		88,241
Non-Cash Financing Activities
Debt issued for service contract assets	$ 0		$ 226		$ 0

[1] Excludes the capital assets acquired as part of the acquisition of assets related to the Terra Transaction and the Rothsay Acquisition in fiscal 2013 of approximately $167.0 million and the BioPur acquisition in fiscal 2012 of approximately $0.6 million